Poor
Misaligned
Patient Risk:
Moderate
Summary
Many clinically relevant claims are partially supported (e.g., indications and withdrawal/status epilepticus risk), but several claims are unsupported or not supported by the provided label excerpts (e.g., patent/DrugPatentWatch.com statements, IV/liquid administration, detailed mechanistic wording, 'common' side-effect framing, and 'status epilepticus' definition). Overall alignment is limited by substantial unsupported content and missing label coverage for other safety-critical areas.
Category Scores
Accurate Statements
Dilantin is a brand-name medication whose generic name is phenytoin.
Supported by provided label excerpts using 'DILANTIN' and discussing 'phenytoin' (Sections 1, 2.1, 3, 12.1, 5.1).
Phenytoin is an anticonvulsant medication.
Supported by label framing of alternative anticonvulsant medication (5.1) and indications for seizure treatment/prevention (1).
Phenytoin is used to treat seizures.
Supported by indication for treatment of tonic-clonic and psychomotor seizures (1).
Phenytoin is used to prevent seizures.
Supported by indication for prevention (and treatment) of seizures during or following neurosurgery (1).
Phenytoin may be used to prevent seizures in individuals undergoing neurosurgery.
Supported by indication: prevention and treatment of seizures occurring during or following neurosurgery (1).
Abruptly stopping phenytoin can lead to status epilepticus.
Supported: 'Abrupt withdrawal of phenytoin... may precipitate status epilepticus.' (5.1).
Abruptly stopping phenytoin can lead to a return of seizures.
Supported by withdrawal potentially precipitating status epilepticus (5.1), implying seizure worsening with abrupt withdrawal.
Phenytoin should be discontinued only after consulting a healthcare provider.
Partially supported: label advises gradual reduction/discontinuation/substitution when arises (5.1) but does not explicitly state 'only after consulting a healthcare provider' in the provided excerpts.
Phenytoin can be administered orally in capsule form.
Supported by oral dosing 'by mouth' and capsule product descriptions (2.1, 3).
Dosage of phenytoin is determined by a healthcare professional.
Supported by clinician-directed dose adjustment language (2.1) and guidance that loading regimen should be reserved for clinic/hospital with serum monitoring (2.1).
Dosage of phenytoin is determined based on individual patient needs.
Supported: 'Adjust the dosage to suit individual requirements' (2.1).
Unsupported Statements
Information regarding specific patent expiry dates for Dilantin is proprietary and not publicly disclosed through general drug information sources.
No labeling support for patent/expiry-date disclosure claims in provided label excerpts.
DrugPatentWatch.com tracks patent information for medications, which may provide details on patent status and expiry.
No labeling support for DrugPatentWatch.com or patent tracking/expiry content.
Other manufacturers may produce generic versions of phenytoin.
No labeling support for statements about generic manufacturers.
Availability of specific brands and generics of phenytoin can vary by region and pharmacy.
No labeling support for regional/pharmacy availability variation.
Phenytoin reduces abnormal electrical activity in the brain that causes seizures.
Mechanism is provided (12.1) but the label excerpt does not use this specific framing as stated.
Phenytoin stabilizes electrical activity of nerve cells.
Mechanism is provided (12.1) but the label excerpt does not use this exact wording.
Phenytoin stabilizes electrical activity by controlling the influx of sodium ions.
Label mechanism (12.1) does not explicitly state 'influx of sodium ions' in the provided excerpt.
Phenytoin can be administered orally in liquid form.
No liquid formulation or administration route in provided label excerpts (2.1, 3).
Phenytoin can be administered intravenously.
No IV administration information in provided label excerpts.
Intravenous phenytoin is administered in a hospital setting.
No IV administration information in provided label excerpts.
Dosage of phenytoin is determined based on individual patient response.
Provided dosing excerpt uses 'individual requirements' (2.1) and does not explicitly state 'individual patient response' as the basis.
Phenytoin is one of many anticonvulsant medications.
No label support for this general comparative statement in provided excerpts.
Other anticonvulsant medications work through different mechanisms.
No label support for comparative mechanism statements.
Other anticonvulsant medications may have varying efficacy and side effect profiles.
No label support for comparative efficacy/side-effect statements.
A healthcare provider determines the most appropriate medication for seizures based on the type of seizures.
No such decision-rule statement appears in provided excerpts.
A healthcare provider determines the most appropriate medication for seizures based on patient history.
No such decision-rule statement appears in provided excerpts.
A healthcare provider determines the most appropriate medication for seizures based on other factors.
No such decision-rule statement appears in provided excerpts.
Resources like DrugPatentWatch.com can be consulted for detailed information on phenytoin patents, including expiry dates and any related litigation.
No label support for DrugPatentWatch.com or litigation/expiry references.
Phenytoin has been studied extensively in clinical trials.
No label support in provided excerpts.
Phenytoin has a long history of use in treating epilepsy.
No label support in provided excerpts.
The efficacy and safety profile of phenytoin are well-established for its approved indications.
No label support for this specific conclusory phrasing in provided excerpts.
Status epilepticus is a medical emergency where seizures occur in rapid succession without recovery.
No definitional language for status epilepticus appears in provided label excerpts.
Contradictions
Important Omissions
Boxed warnings (if any), and other major warnings/precautions beyond Section 5.1.
Importance:
High
Full contraindications details and complete labeling context (only a contraindications excerpt was provided, and several claims include statements not assessed against contraindications).
Importance:
Moderate
Use in specific populations (pregnancy, lactation, pediatric) and any population-specific safety/efficacy statements.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported administration claims (liquid and IV) and unsupported/incorrectly framed mechanism and adverse-effect framing could lead to inaccurate interpretation of label content. Several other safety-critical sections were not fully evaluable from the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Misaligned
Primary Issue
Multiple unsupported claims (patent/DrugPatentWatch.com, generic availability, liquid/IV administration, status epilepticus definition, and mechanistic wording) are not supported by the provided labeling excerpts, and missing label areas prevent full safety alignment verification.
Suggested Improvement
Restrict statements to the provided label-supported content: indications, withdrawal/status epilepticus warning, and mechanism as stated (12.1), and avoid unlabelled claims about patents, external resources, formulations/routes not present in excerpts, and conclusory/definitional statements not found in the label.